期刊文献+

慢性心功能不全药物治疗的研究进展 被引量:2

The progress of CHF medical treatments
下载PDF
导出
摘要 目的:论述慢性心功能不全(CHF)药物治疗的国内外研究进展。方法:复习近年来国内外有关CHF药物治疗的试验,并结合临床经验进行归纳与分析。结果:对心衰发生与发展机制的认识经历了心-肾机制、心脏-周围循环机制及神经-体液机制3个阶段。CHF的药物治疗主要有血管紧张素转换酶抑制剂(ACEl)、β-受体阻滞剂、利尿剂、洋地黄制剂及非洋地黄类正性肌力药、血管紧张素受体拮抗剂(ARB)和醛固酮拮抗剂。结论:CHF的药物治疗近年来已取得显著进步,降低了CHF患者的病死率和住院率。 Objective: Having a investigation into the CHF medical treatments research condition at home and abroad. Methods: Conducting a survey of the related experiments of the CHF medical treatments at home and abroad combined with the clinical experience treats. Resuits: Of the causes and underlying reasons of the disease , the scientific studies have past three stages : the Heart - kidney mechanism , the Heart- Periphery circulatory mechanism , and the Nerve - Body fluid mechanism. Medications used to treat CHF mainly include the following : Angiotensin - converting enzyme inhibitors (ACEI), Beta - blokers, Diuresis, Digitalis preparation, Non - Digitalis myo - strength medicines, Angiotensin Ⅱ receptor blocker(ARB), Aldosterone oppresses the anti- medicinal preparation blockers. Conclusions: Substantial achievements have been made in the CHF medical treatments research with a lower percentage of patients becoming dead or being hospitalized.
作者 李砚池
出处 《中国民康医学》 2006年第14期542-544,546,共4页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献4

二级参考文献24

  • 1MERIT-HF Study Group.Effect of metoprolol CR/XL Randomized Intervention trial in congestive heart failure(MERIT-HF).Lancet,1999,353(9169):2001. 被引量:1
  • 2Waagstein F,Bristow MR Swedberg K,et al.Beneficial of metoprolol in idiopathic dilated cardiomyopathy.Lancet,1993,342:1441. 被引量:1
  • 3Colucci WS,Packer M,Bristow MR,et al.Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure.US Carvediolo Heart Failure Study Group.Circulation,1996,94:2800. 被引量:1
  • 4Packer M,Colucci WS,Sacker-Bernstein JD,et al.Double-blind place bocontrolled study of the effect of carvedilol in PRECISE trial.Circulation,1996,94:2793. 被引量:1
  • 5Packer M,Coats AJS,Flower MB,et al.Effect of carvedilol on survival in sever chronic heart failure.N Engl J Med,2001,344:1651-1658. 被引量:1
  • 6Packer M,Bristow M,Cohn J,et al.for the US carvedilol heart failure study group.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.N Engl J Med,1996,334:1349. 被引量:1
  • 7Bristow MR.Mechanism of action of beta-blocking agent in heart failure.Am J Cardiol,1997,80:26. 被引量:1
  • 8Esler M,Kaye D,Lambert G,et al.Adrenergic nervous system in heart failure.Am J Cardiol,1997,80:7. 被引量:1
  • 9Eichhorn EJ,Bristow MR.Medical therapy can improve the biological properities of the chronically failing heart:a new era in the treatment of heart failure.Circulation,1996,94:2285. 被引量:1
  • 10Colucci W.Molecular and cellular mechanisms of myocardial failure.Am J Cardiol,1997,80:15. 被引量:1

共引文献162

同被引文献18

  • 1蔺虹,张媛华.丹红注射液对脑梗死患者血脂及血液流变学的影响[J].云南中医中药杂志,2007,28(6):20-21. 被引量:23
  • 2罗俊,燕纯伯.瑞舒伐他汀抗动脉粥样硬化的临床应用进展[J].心血管病学进展,2007,28(3):480-483. 被引量:53
  • 3Lee SE, Choi DJ, Yoon CH,et al. Improvement of hyponatraemia duringhospitalisation for acute heartfailure is not associated with improvement ofprognosis : an analysis from the Korean Heart Failure (KorHF) registry.Heart ,2012,98:1798-1804. 被引量:1
  • 4Sato N,Gheorghiade M, Kajimoto K,et al. Hyponatremia and in-hospitalmortality in patients admitted for heart failure ( from the ATTEND regis-try). Am J Cardiol,2013,111 : 1019-1025. 被引量:1
  • 5蔡光先,赵玉庸主编.中西医结合内科学.第1版.北京:中国中医药出版社,2005.198. 被引量:2
  • 6David A, Morrow MD,Michael M, et al. Modulation of myocardial ener-getics :emerging evidence for a therapeutic target ill cardiovascular disease. Circulation,2005,112:3218-3221. 被引量:1
  • 7Deardorff R, Spinaale FG. Cytokines and matrix metalloproteinase as po-tential biomarkers chronic heart failure. Biomark Med,2009,3:513-523. 被引量:1
  • 8Go AS,Lee WY, Yang J,et al. Statin therapy and risks for death andhospitalization in chronic heart failure. JAMA,2006,296:2105-2111. 被引量:1
  • 9DiNicolantonio JJ, Lavie CJ, Serebruany VL, et al. Statin wars: theheavyweight match-atorvastatin versus rosuvastatin for the treatment ofatherosclerosis,heart failure,and chronic kidney disease. Postgrad Med,2013,125:7-16. 被引量:1
  • 10Askevold ET,Nymo S,Ueland T,et al. Soluble glycoprotein 130 predictsfatal outcomes in chronic heart failure : analysis from the Controlled Ro-suvastatin Multinational Trial in Heart Failure (CORONA). Circ HeartFail,2013,6..91-98. 被引量:1

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部